Werntz RP - Search Results

1

Testicular Cancer: Epidemiology, Diagnosis, and Management.

Smith ZL, Werntz RP, Eggener SE. Smith ZL, et al. Among authors: werntz rp. Med Clin North Am. 2018 Mar;102(2):251-264. doi: 10.1016/j.mcna.2017.10.003. Epub 2017 Dec 21. Med Clin North Am. 2018. PMID: 29406056 Review.

2

Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.

Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Labbate C, et al. J Immunother Cancer. 2019 Mar 11;7(1):66. doi: 10.1186/s40425-019-0546-8. J Immunother Cancer. 2019. PMID: 30857555 Free PMC article.

3

Novel focal therapy treatment options for prostate cancer.

Werntz RP, Eggener SE. Werntz RP, et al. Curr Opin Urol. 2018 Mar;28(2):178-183. doi: 10.1097/MOU.0000000000000469. Curr Opin Urol. 2018. PMID: 29232270 Review.

4

Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection.

Werntz RP, Pearce SM, Eggener SE. Werntz RP, et al. Curr Opin Urol. 2018 Sep;28(5):461-468. doi: 10.1097/MOU.0000000000000530. Curr Opin Urol. 2018. PMID: 29979235 Review.

5

Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later.

Riedinger CB, Labbate C, Werntz RP, Eggener SE. Riedinger CB, et al. Among authors: werntz rp. Urology. 2018 Dec;122:16-18. doi: 10.1016/j.urology.2018.08.014. Epub 2018 Aug 28. Urology. 2018. PMID: 30170087 No abstract available.

6

The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy.

Werntz RP, Smith ZL, Packiam VT, Smith N, Steinberg GD. Werntz RP, et al. Eur Urol Focus. 2020 Mar 15;6(2):292-297. doi: 10.1016/j.euf.2018.09.019. Epub 2018 Oct 5. Eur Urol Focus. 2020. PMID: 30297221

7

The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma.

Werntz RP, Riedinger CB, Fantus RJ, Smith ZL, Packiam VT, Adamsky MA, Smith N, Steinberg GD. Werntz RP, et al. Urol Oncol. 2018 Dec;36(12):526.e1-526.e6. doi: 10.1016/j.urolonc.2018.09.014. Epub 2018 Nov 13. Urol Oncol. 2018. PMID: 30446445

8

Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.

Werntz RP, Eggener SE. Werntz RP, et al. Eur Urol. 2019 Aug;76(2):252. doi: 10.1016/j.eururo.2019.03.041. Epub 2019 Apr 5. Eur Urol. 2019. PMID: 30962042 No abstract available.

9

Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors.

Werntz RP, Eggener SE. Werntz RP, et al. Transl Androl Urol. 2020 Jan;9(Suppl 1):S31-S35. doi: 10.21037/tau.2019.06.20. Transl Androl Urol. 2020. PMID: 32055483 Free PMC article. Review.

10

National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.

Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SE. Labbate CV, et al. Among authors: werntz rp. Urol Oncol. 2020 Aug;38(8):687.e13-687.e18. doi: 10.1016/j.urolonc.2020.03.014. Epub 2020 Apr 15. Urol Oncol. 2020. PMID: 32305267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page